Teleflex Inc (TFX)

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications in the United States, Europe, the Middle East, Africa, the Asia Pacific, and internationally. The company offers vascular and emergency medicine products comprising Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous bone access systems for the administration of intravenous therapies, measurement of blood pressure, and collection of blood samples; intraosseous access systems consisting of EZ-IO intraosseous vascular access systems, and Arrow FAST1 sternal intraosseous infusion systems; and hemostatic products, including external hemostats and trauma products under the QuikClot brand. It also provides interventional products, including various coronary catheters, structural heart support devices, and peripheral intervention products platforms; GuideLiner, Turnpike, and TrapLiner catheters; MANTA vascular closure devices and Arrow OnControl powered bone biopsy systems; and coronary and peripheral medical devices, such as drug-coated balloons, stents, and balloon catheters. In addition, the company offers surgical products, including metal and polymer ligating clips using manual and automatic applier system, fascial closure surgical systems used in laparoscopic surgical procedures, percutaneous surgical systems, powered bariatric staplers, and other surgical instruments under the Weck, MiniLap, Pleur-Evac, Deknatel, KMedic, Pilling, and Titan SGS brands. It serves hospitals, healthcare providers, and medical device manufacturers. The company also sells its products online. Teleflex Incorporated was incorporated in 1943 and is headquartered in Wayne, Pennsylvania.

Symbol
TFX
Exchange
NYSE
Sector
Healthcare
Industry
Medical Instruments & Supplies
Market cap
$5.44B
52 week range
100.18 - 145

Valuation

Share price
$121.75 (close of 2026-09-23)
P/E (TTM)
-5.37x
Price to book
1.87x
Price to free cash flow
32.31x
Enterprise value
$8.01B
Book value per share
$66.68

Price performance

PeriodChange
1 day-2.44%
5 days-5.63%
1 month-12.30%
3 months-2.02%
6 months+15.02%
Year to date-0.24%
1 year-0.29%
3 years-40.32%
5 years-68.72%
10 years-29.03%
All time+7857.52%

Profitability and growth

Return on equity
-28.98%
Return on invested capital
2.16%
Return on assets
-13.04%
Return on capital employed
1.91%
Gross margin
56.24%
Net margin
-45.45%
EBITDA margin
14.86%
Revenue growth
17.25%
Net income growth
-1399.81%
Free cash flow growth
-99.32%

Cash flow and balance sheet

Free cash flow yield (TTM)
3.10%
Current ratio
2.60x
Net debt to EBITDA
14.76x

Latest reported year

Period end
2025-12-31
Fiscal year
2025
Revenue
$1.99B
Cost of revenue
$871.96M
Gross profit
$1.12B
EBITDA
$296.11M
Net income
$-905.64M
Earnings per share
$-20.30
Research and development
$144.78M
Shares outstanding
44.62M

Income statement by year

Period endRevenueGross profitNet incomeEPS
2025-12-31$1.99B$1.12B$-905.64M$-20.30
2024-12-31$1.70B$1.04B$69.67M$1.49
2023-12-31$1.71B$1.04B$356.33M$7.58
2022-12-31$2.79B$1.53B$363.14M$7.74
2021-12-31$2.81B$1.55B$485.37M$10.38
2020-12-31$2.54B$1.32B$335.32M$7.21
2019-12-31$2.60B$1.41B$461.47M$9.99
2018-12-31$2.45B$1.30B$200.80M$4.39
2017-12-31$2.15B$1.17B$152.53M$3.39
2016-12-31$1.87B$996.20M$237.38M$5.48

Margins and returns by year

Period endGross marginNet marginReturn on equityReturn on capital
2025-12-3156.24%-45.45%-28.98%2.16%
2024-12-3161.04%4.10%1.63%1.80%
2023-12-3160.74%20.81%8.02%3.53%
2022-12-3154.86%13.01%9.03%7.49%
2021-12-3155.15%17.28%12.93%10.50%
2020-12-3152.22%13.22%10.05%7.26%
2019-12-3154.29%17.78%15.49%9.11%
2018-12-3153.21%8.20%7.91%6.88%
2017-12-3154.60%7.11%6.28%5.58%
2016-12-3153.33%12.71%11.11%11.85%

Cash and debt by year

Period endCashDebt
2025-12-31$378.56M$2.54B
2024-12-31$247.85M$1.56B
2023-12-31$222.85M$1.73B
2022-12-31$292.03M$1.62B
2021-12-31$445.08M$1.74B
2020-12-31$375.88M$2.38B
2019-12-31$301.08M$1.86B
2018-12-31$357.16M$2.07B
2017-12-31$333.56M$2.16B
2016-12-31$543.79M$850.25M

Free cash flow by year

Period endFree cash flowStock-based compensation
2025-12-31$1.45M$25.70M
2024-12-31$211.44M$25.96M
2023-12-31$159.72M$27.30M
2022-12-31$263.62M$27.22M
2021-12-31$580.52M$22.94M
2020-12-31$346.45M$20.74M
2019-12-31$334.37M$26.94M
2018-12-31$354.29M$22.44M
2017-12-31$355.40M$19.41M
2016-12-31$357.45M$16.87M

Dividend history

Most recent payment
2026-08-14
Paid in the last twelve months
$1.36
Payment dateDividend per share
2026-08-14$0.34
2026-05-22$0.34
2026-03-06$0.34
2025-11-14$0.34
2025-08-15$0.34
2025-05-20$0.34
2025-03-07$0.34
2024-11-15$0.34

Investor relations

Next earnings report

Next confirmed report
2026-11-05
Consensus EPS estimate
$1.92

Past earnings dates

ReportedFiscal periodEPS estimate
2026-08-06Jun/2026$1.28
2026-05-07--
2026-02-26--
2025-11-06--
2025-07-31--
2025-05-01--
2025-02-27--
2024-10-31--

Filings and sources

Company website
teleflex.com
SEC filings
10-K, 10-Q and 8-K on EDGAR
Earnings calendar
All upcoming reports

Similar companies

Intuitive Surgical Inc (ISRG) · Becton Dickinson & Co (BDX) · ResMed Inc (RMD) · West Pharmaceutical Services Inc (WST) · Baxter International Inc (BAX) · Align Technology Inc (ALGN) · Cooper Companies, Inc. (COO) · Vertex Pharmaceuticals Inc (VRTX)

All Healthcare companies

Understanding these figures

Price-to-earnings ratio · Discounted cash flow · Free cash flow · Earnings per share · Return on equity · Gross margin vs net margin · Reading a balance sheet · Debt and leverage · Dividend yield · Insider transactions and Form 4 · How to read a stock chart

Explore

Company directory · S&P 500 heatmap · Earnings calendar · Super investor holdings · Congress trades